Home Alzheimer’s Disease Longer OS Observed for N1 Prostate Cancer Treated at Facilities with High...

Longer OS Observed for N1 Prostate Cancer Treated at Facilities with High Radiation Case Volume

A study published in JAMA Network Open revealed that for men with N1 prostate cancer undergoing external beam radiation therapy (EBRT) with concomitant androgen deprivation therapy (ADT), treatment at a facility with high radiation case volume, regardless of academic affiliation, was correlated with longer overall survival (OS).

“Numerous studies have shown that patients with cancer who are treated at high-volume facilities have higher rates of long-term survival, including those who undergo primary surgery, radiation, or chemotherapy,” wrote the study authors, led by Sagar A. Patel, MD. “Given the complexity of management of N1 prostate cancer, we hypothesized that men treated at high-volume centers would have improved OS compared with those treated at low-volume centers.”

To evaluate the association between radiation facility case volume and OS among men with N1 prostate…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Toni Choueiri, MD, on What Multidisciplinary Stakeholders Should Know About CheckMate 9ER

Results from the phase 3 CheckMate 9ER trial (NCT03141177) presented at the American Society of Clinical Oncology (ASCO) 2021 Genitourinary Cancer Symposium revealed that...

Robert J. Motzer, MD, on the Rationale for the Phase 3 CheckMate 9ER Trial in Advanced RCC

Compared with sunitinib (Sutent), combination treatment with nivolumab and cabozantinib demonstrated improved efficacy and prolonged survival among patients with previously treated advanced renal cell...

PHERGain II Trial Launched to Examine Chemotherapy-Free Treatment for Patients With HER2+ Breast Cancer

A clinical trial to support the use of a chemotherapy-free therapeutic approach has been launched and will aim to demonstrate that this approach is...

FDA Grants Breakthrough Therapy Designation to Tipifarnib for Treatment of HRAS-Mutant HNSCC

The FDA has granted breakthrough therapy designation to the investigational drug tipifarnib for the treatment of patients with recurrent or metastatic HRAS-mutant head and...

Recent Comments